Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill Lecture.
Figure: Age-adjusted cancer death rates per 100,000 U.S. men, by tumor site (American Cancer Society)For men in the U.S., prostate cancer is the second-leading cause of cancer death. Not all prostate cancers are the same, and researchers have learned much about the genetic changes and cell signaling modifications that make prostate tumors behave differently. Understanding the differences most important for cancer aggressiveness and treatment decision-making will be the focus of a public talk on May 17 by oncologist Joshi Alumkal, M.D.
Thursday, May 17, 7 p.m.
Collaborative Life Sciences Building
Alumkal is the Wayne D. Kuni & Joan E. Kuni Foundation Endowed Chair for Prostate Cancer Research, an associate professor of medicine in the OHSU School of Medicine and co-leader of the Knight Cancer Institute Prostate Cancer Research Program. In his presentation, Alumkal will describe how engaging patients as partners has significantly improved the ability to understand the blueprint of advanced prostate cancer and develop new treatments to control the disease more effectively. His research team recently uncovered a signaling pathway that prostate cancers use to evade hormonal therapies. The findings set the stage for developing a new treatment approach to block lethal prostate cancer.
Since 1981, the Marquam Hill Lecture Series has brought together leading members of the OHSU faculty with the public for free lectures which feature innovative and cutting edge biomedical research and clinical advances that will form the basis of tomorrow’s cures and treatments.